GlycoMimetics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
GLYC Nasdaq 2836 www.glycomimetics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for GlycoMimetics, Inc.

GlycoMimetics and Crescent Biopharma Announce Merger Plans - Jan 14th, 2025 2:34 pm
GlycoMimetics: Q3 Earnings Snapshot - Nov 13th, 2024 10:15 pm
Crescent Biopharma to Present at Jefferies London Healthcare Conference 2024 - Nov 12th, 2024 1:00 pm
GlycoMimetics Announces New Uproleselan Clinical Data Will Be Presented at ASH Annual Meeting - Nov 6th, 2024 12:00 pm
US Penny Stocks To Watch In October 2024 - Oct 30th, 2024 5:07 pm
GlycoMimetics Announces Merger with Crescent Biopharma - Oct 30th, 2024 12:31 pm
GlycoMimetics Enters Into Acquisition Agreement With Crescent Biopharma - Oct 29th, 2024 11:00 am
GlycoMimetics Announces National Cancer Institute Phase 2/3 Study of Uproleselan Did Not Meet Primary Endpoint - Oct 29th, 2024 10:30 am
GlycoMimetics Announces Strategic Review and Corporate Restructuring Plan - Jul 25th, 2024 1:00 pm
7 Sorry Biotech Stocks Set to Make Investors Sad - Jul 22nd, 2024 11:00 am
Senior VP & Chief Medical Officer of GlycoMimetics Edwin Rock Buys 81% More Shares - Jun 26th, 2024 10:07 am
GlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) - Jun 4th, 2024 11:00 am
GlycoMimetics to Host Key Opinion Leader Event to Review Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) on June 4, 2024 - May 29th, 2024 8:01 pm
Pipeline Moves: Phase III AML trial fails to meet primary endpoint - May 28th, 2024 8:05 am
Uproleselan’s failed Phase III AML trial shakes up GlycoMimetics’ future - May 8th, 2024 11:42 am
GlycoMimetics reports data from Phase III AML treatment trial - May 7th, 2024 9:21 am
GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) - May 6th, 2024 10:00 am
We're Keeping An Eye On GlycoMimetics' (NASDAQ:GLYC) Cash Burn Rate - Apr 28th, 2024 2:10 pm
GlycoMimetics to Report First Quarter 2024 Financial Results on May 9, 2024 - Apr 25th, 2024 11:00 am
Loss-Making GlycoMimetics, Inc. (NASDAQ:GLYC) Expected To Breakeven In The Medium-Term - Apr 1st, 2024 12:41 pm